These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 29760144)

  • 1. Personalizing Polymyxin B Dosing Using an Adaptive Feedback Control Algorithm.
    Lakota EA; Landersdorfer CB; Nation RL; Li J; Kaye KS; Rao GG; Forrest A
    Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29760144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parenteral polymyxin B use in patients with multidrug-resistant gram-negative bacteremia and urinary tract infections: a retrospective case series.
    Pastewski AA; Caruso P; Parris AR; Dizon R; Kopec R; Sharma S; Mayer S; Ghitan M; Chapnick EK
    Ann Pharmacother; 2008 Sep; 42(9):1177-87. PubMed ID: 18664609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aerosolized Polymyxin B for Treatment of Respiratory Tract Infections: Determination of Pharmacokinetic-Pharmacodynamic Indices for Aerosolized Polymyxin B against Pseudomonas aeruginosa in a Mouse Lung Infection Model.
    Lin YW; Zhou Q; Onufrak NJ; Wirth V; Chen K; Wang J; Forrest A; Chan HK; Li J
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic/pharmacodynamic adequacy of polymyxin B against extensively drug-resistant Gram-negative bacteria in critically ill, general ward and cystic fibrosis patient populations.
    Xie J; Roberts JA; Lipman J; Cai Y; Wang H; Zhao N; Xu X; Yang S; Li Y; Zhang K
    Int J Antimicrob Agents; 2020 Jun; 55(6):105943. PubMed ID: 32184115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination therapy with polymyxin B for the treatment of multidrug-resistant Gram-negative respiratory tract infections.
    Sobieszczyk ME; Furuya EY; Hay CM; Pancholi P; Della-Latta P; Hammer SM; Kubin CJ
    J Antimicrob Chemother; 2004 Aug; 54(2):566-9. PubMed ID: 15269195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and pharmacodynamics of polymyxin B and proposed dosing regimens in elderly patients with multi-drug-resistant Gram-negative bacterial infections.
    Wang P; Liu D; Sun T; Zhang X; Yang J
    Int J Antimicrob Agents; 2022; 60(5-6):106693. PubMed ID: 36375775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. To B or not to B, that is the question: is it time to replace colistin with polymyxin B?
    Kassamali Z; Danziger L
    Pharmacotherapy; 2015 Jan; 35(1):17-21. PubMed ID: 25346395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Colistin versus polymyxin B for the treatment of patients with multidrug-resistant Gram-negative infections: a systematic review and meta-analysis.
    Vardakas KZ; Falagas ME
    Int J Antimicrob Agents; 2017 Feb; 49(2):233-238. PubMed ID: 27686609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review.
    Zavascki AP; Goldani LZ; Li J; Nation RL
    J Antimicrob Chemother; 2007 Dec; 60(6):1206-15. PubMed ID: 17878146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymyxin B: a new strategy for multidrug-resistant Gram-negative organisms.
    Yuan Z; Tam VH
    Expert Opin Investig Drugs; 2008 May; 17(5):661-8. PubMed ID: 18447592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population Pharmacokinetics of Polymyxin B in Acutely Ill Adult Patients.
    Miglis C; Rhodes NJ; Avedissian SN; Kubin CJ; Yin MT; Nelson BC; Pai MP; Scheetz MH
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29311071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetics and clinical outcomes of polymyxin B in paediatric patients with multidrug-resistant Gram-negative bacterial infections.
    Wang PL; Liu P; Zhang QW; Yuan WH; Wang D; Zhang XJ; Yang J
    J Antimicrob Chemother; 2022 Oct; 77(11):3000-3008. PubMed ID: 35924405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polymyxin B clinical outcomes: A prospective study of patients undergoing intravenous treatment.
    Mattos KPH; Gouvêa IR; Quintanilha JCF; Cursino MA; Vasconcelos PENS; Moriel P
    J Clin Pharm Ther; 2019 Jun; 44(3):415-419. PubMed ID: 30666679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus.
    Nation RL; Li J; Cars O; Couet W; Dudley MN; Kaye KS; Mouton JW; Paterson DL; Tam VH; Theuretzbacher U; Tsuji BT; Turnidge JD
    Lancet Infect Dis; 2015 Feb; 15(2):225-34. PubMed ID: 25459221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of polymyxin B-induced nephrotoxicity: implications for dosing regimen design.
    Abdelraouf K; Braggs KH; Yin T; Truong LD; Hu M; Tam VH
    Antimicrob Agents Chemother; 2012 Sep; 56(9):4625-9. PubMed ID: 22687519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetic and optimization of polymyxin B dosing in adult patients with various renal functions.
    Yu XB; Jiao Z; Zhang CH; Dai Y; Zhou ZY; Han L; Wen X; Sheng CC; Lin GY; Pan JY
    Br J Clin Pharmacol; 2021 Apr; 87(4):1869-1877. PubMed ID: 33002196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polymyxin B nephrotoxicity and efficacy against nosocomial infections caused by multiresistant gram-negative bacteria.
    Ouderkirk JP; Nord JA; Turett GS; Kislak JW
    Antimicrob Agents Chemother; 2003 Aug; 47(8):2659-62. PubMed ID: 12878536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal Empiric Polymyxin B Treatment of Patients Infected with Gram-Negative Organisms Detected Using a Blood Antimicrobial Surveillance Network in China.
    Wu X; Huang C; Wang H; Ji J; Ying C; Xiao Y
    Drug Des Devel Ther; 2021; 15():2593-2603. PubMed ID: 34168431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polymyxin B for Gram Negative Multidrug Resistant Bacteria in a Hispanic Population.
    De León-Borrás R; Sánchez-Sergentón C; Mayor-Becerra A; Laureano-Cuadrado AF
    P R Health Sci J; 2019 Mar; 38(1):15-21. PubMed ID: 30924910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An update on the arsenal for multidrug-resistant Acinetobacter infections: polymyxin antibiotics.
    Kassamali Z; Jain R; Danziger LH
    Int J Infect Dis; 2015 Jan; 30():125-32. PubMed ID: 25461655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.